Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
Authors
Kim Papp (ORCID: https://orcid.org/0000-0001-9557-3642)
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
Kim Papp, Michio Yagi, JungBin Cha, Eunkyung Euni Lee et al.
Journal
Expert Opinion on Investigational Drugs
Topics
Biosimilars and Bioanalytical Methods
article
Pharmacokinetics and safety of candidate biosimilar CT-P55 versus reference secukinumab: a three-arm, randomized, double-blinded, single-dose, multicenter, Phase I study
University of Toronto (CA), Alliance for Clinical Trials in Oncology (US), Probity Medical Research (CA), Kitasato Institute Hospital (JP), Celltrion (South Korea) (KR), Kitasato University (JP), University of Lübeck (DE)